Explore ChatPEP
Resources
Plans
Explore research
Browse by goal
Popular peptides
Explore news
Topics
Latest
Explore company
Support
Legal
Every post on regulatory, newest first.
Studies·Sep 17, 2026·6 min read
A 2026 clinical note review found documented BPC-157 use rose 33-fold over six years, with new users skewing younger and male. A separate rat tendon study showed TB-500 or the combination improved architecture more consistently than BPC-157 alone.
The evergreen research summaries these posts build on.